NCT06998381 Ethnic Specificities of S100B Protein Blood Level in Guadeloupe: Cross-sectional Study in Healthy Subjects
| NCT ID | NCT06998381 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire de la Guadeloupe |
| Condition | s100b |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2023-02-01 |
| Primary Completion | 2025-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2023-02-01 with a primary completion date of 2025-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Numerous studies have demonstrated the significant contribution of S100B blood level measurement in the management of minor to moderate traumatic brain injuries, notably by reducing the number of cranial computed tomography (CT) scans by at least one-third. However, physiological blood concentrations of the S100B protein may be higher in individuals with a Black phenotype compared to those with Asian or, in particular, Caucasian phenotypes. Assessing S100B protein levels in healthy individuals will help confirm the variability of its physiological concentration according to skin phenotype.
Eligibility Criteria
Inclusion Criteria : * Hospital staff of the University Hospital of Guadeloupe or the Hospital of Basse-Terre * Age between 18 and 65 years * Individuals willing to specify their ethnic origin and skin phototype * Individuals affiliated with or beneficiaries of a social security scheme * Informed individuals who have given their voluntary, informed, and written consent Exclusion Criteria : * Individuals on anticoagulant therapy * Individuals with a personal history of neurological disease * Individuals with a personal history of melanoma * Refusal to participate * Individuals under guardianship, curatorship, or legal protection
Contact & Investigator
Delphine Delta, MD
PRINCIPAL INVESTIGATOR
CHU de la Guadeloupe
Frequently Asked Questions
Who can join the NCT06998381 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying s100b. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06998381 currently recruiting?
Yes, NCT06998381 is actively recruiting participants. Contact the research team at valerie.soter@chu-guadeloupe.fr for enrollment information.
Where is the NCT06998381 trial being conducted?
This trial is being conducted at Basse-Terre, Guadeloupe, Pointe-à-Pitre, Guadeloupe.
Who is sponsoring the NCT06998381 clinical trial?
NCT06998381 is sponsored by Centre Hospitalier Universitaire de la Guadeloupe. The principal investigator is Delphine Delta, MD at CHU de la Guadeloupe. The trial plans to enroll 200 participants.